Sort
10,766 grants matching “checkpoint inhibitor”
Predictive biomarker of BET bromodomain inhibitor in Small cell lung cancer
$243,898Haobin Chen · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
HDAC4 Viability: Unique Mechanisms and Function
$243,771Gary D Kao · University Of Pennsylvania · R01 · FY2006 · CA
Regulation of CD4+ T cell responses during chronic viral infection
$243,750Linda Mac Pherson Bradley · Sanford Burnham Prebys Medical Discovery Institute · R21 · FY2021 · AI
CD44 Promotes Chronic Virus Infection
$243,750Linda Mac Pherson Bradley · Sanford Burnham Prebys Medical Discovery Institute · R21 · FY2019 · AI
DCLK1 and regulation of the DNA damage response in proximal tubule injury
$243,750Parker C. Wilson · University Of Pennsylvania · R03 · FY2025 · DK
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
$243,567Noah M Hahn · Johns Hopkins University · R01 · FY2024 · CA
Checkpoint abrogation and MEK1/2 inhibition in myeloma
$243,515Steven Grant · Virginia Commonwealth University · R01 · FY2006 · CA
Molecular Mode of Action of JAB-1 in Cell Proliferation
$243,515Francois X Claret · University Of Tx Md Anderson Can Ctr · R01 · FY2006 · CA
Project 2
$243,390Tomas Kirchhoff · New York University School Of Medicine · P50 · FY2024 · CA
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer
$243,205Byron H Lee · Cleveland Clinic Lerner Com-Cwru · K08 · FY2021 · CA
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer
$243,205Byron H Lee · Cleveland Clinic Lerner Com-Cwru · K08 · FY2020 · CA
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer
$243,205Byron H Lee · Cleveland Clinic Lerner Com-Cwru · K08 · FY2022 · CA
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer
$243,205Byron H Lee · Cleveland Clinic Lerner Com-Cwru · K08 · FY2019 · CA
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer
$243,205Byron H Lee · University Of Tx Md Anderson Can Ctr · K08 · FY2023 · CA
Experimental Therapeutics Program
$243,163John D Minna · Ut Southwestern Medical Center · P30 · FY2025 · CA
DC AML Fusion Cell Vaccination with Immune checkpoint Blockade
$243,163Gordon James Freeman · Brigham And Women'S Hospital · P50 · FY2018 · CA
Tumor Immune Profiling to Optimize Clinical Trial Readiness in Basal Cell Nevus Syndrome
$243,000David Rinsey Bickers · Columbia University Health Sciences · R21 · FY2021 · TR
Quantitative High Throughput Screening for Small Molecules Targeting CD47 in Cancer
$242,998Thomas W Miller · Institut Jean Paoli & Irene Calmettes Centre Regional De Lutte Contre Le Cancer · R37 · FY2022 · CA
Mechanisms of CD4 autoreactivity after checkpoint inhibition
$242,969Terri M. Laufer · University Of Pennsylvania · R21 · FY2024 · AI
P53 MEDIATED G2/M CHECKPOINT CONTROL
$242,745Thomas Jefferson University · R01 · FY2001 · CA
Specificity of the Ubiquitin System in Lymphoid Malignancies
$242,678Luca Busino · University Of Pennsylvania · R00 · FY2015 · CA
Role of Acid in the Development of Barrett's Esophagus
$242,663Rhonda F Souza · Ut Southwestern Medical Center · R01 · FY2011 · DK
PI3K opposes p27 and G1 arrest by TGF-B in human cancer
$242,621Joyce Marie Slingerland · University Of Miami School Of Medicine · R01 · FY2006 · CA
Checkpoint Abrogation and MEK 1/2 Inhibition in Myeloma
$242,485Steven Grant · Virginia Commonwealth University · R01 · FY2011 · CA
Checkpoint Abrogation and MEK 1/2 Inhibition in Myeloma
$242,485Steven Grant · Virginia Commonwealth University · R01 · FY2012 · CA